Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07295691
Recruiting Not applicable

Autologous Serum Eye Drops in Dry Eye Syndrome

NCT07295691 · tracked via the Priya Life Science Egypt tracker
Sponsor
The General Authority for Teaching Hospitals and Institutes
Phase
Not applicable
Started
2025-09-01
Last updated
2025-12-22

Condition(s) studied

Autologous Serum Eye DropsDry Eye Syndrome

Investigational drug(s) / intervention(s)

Autologous Serum Eye Drop

Autologous Serum Eye Drop: Participants will receive eye drops prepared from their blood serum following a standardized protocol. Specifically, 40 mL of venous blood was collected from each participant at the start of the study and centrifuged at 3000 rpm for 15 min.

Study summary

This study aims to evaluate the clinical efficacy and safety of autologous serum eye drops (ASEDs) in patients with moderate-to-severe dry eye syndrome who are refractory to conventional artificial tear therapy.

Eligibility

Sex
ALL
Min age
—
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * Children aged less than 18 years. * Both sexes. * Diagnosed with moderate to severe dry eye syndrome (DES) refractory to artificial tears. Exclusion Criteria: * Active ocular infection. * Recent ocular surgery. * Systemic immunosuppressive therapy. * History of allergy to blood-derived products.

Primary outcome measure(s)

  • Visual acuity — 12 weeks post-procedure
    Visual acuity will be measured.

Trial sites (1)

FacilityCityRegionStatus
The General Authority for Teaching Hospitals and Institutes Cairo Egypt Recruiting

More The General Authority for Teaching Hospitals and Institutes trials in Egypt

Non-invasive Diffusion-weighted Imaging With MRCP in the Diagnosis of Neoplastic Biliary Obstruction Recruiting
Micropulse Laser in Treatment of Initial and Refractory Cases of Center-Involved Diabetic Macular Edema Recruiting
Diffusion Magnetic Resonance Imaging (dMRI) in the Early Evaluation of Brain White Matter Diseases Recruiting
Role of Low Dose Injectable Progesterone in Triggering Ovulation Recruiting
Original Denis Brawn Brace Versus Its Modification for Management of Relapsed Idiopathic Clubfoot Following Ponseti Casting Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07295691 on ClinicalTrials.gov ↗ ← All trials in Egypt